 Home > Active Ingredient News > Antitumor Therapy > JCO: The prognosis of stage 3 gefitinib vs. cisplatin + vinorelbine for adjuvant treatment of non-small cell lung cancer after surgical resection

JCO: The prognosis of stage 3 gefitinib vs. cisplatin + vinorelbine for adjuvant treatment of non-small cell lung cancer after surgical resection

 Last Update: 2021-11-13
 Source: Internet
 Author: User

Tags

escitaloprám 10 mg

v617f mutation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Although cisplatin-based adjuvant chemotherapy is the standard treatment for stage II and stage III non-small cell lung cancer ( NSCLC ) that are completely resected by surgery , the survival prognosis of patients is not satisfactory

NSCLC

This study (IMPACT) aims to investigate the efficacy of gefitinib in adjuvant treatment of non-small cell lung cancer patients with EGFR mutations

This is an open-label, randomized phase 3 trial that recruits patients with stage II-III non-small cell lung cancer who have been completely resected with EGFR mutation (exon 19 deletion or L858R mutation) and randomly divided into two groups.

Disease-free survival of the two treatment groups

From September 2011 to 2015, a total of 234 patients were recruited and randomly divided into two groups

The median DFS of the gefitinib group and the cisplatin+vinorelbine group were 35.

In summary, although adjuvant gefitinib therapy seems to prevent early recurrence of non-small cell lung cancer, it does not prolong disease-free survival or overall survival

Gefitinib adjuvant treatment of early recurrence prevented appears NSCLC, but it does not prolong disease-free survival or overall survival gefitinib adjuvant treatment of early recurrence prevented appears NSCLC, but it does not prolong disease Survival period or overall survival period

Original source:

Tada Hirohito, Mitsudomi Tetsuya, Misumi Toshihiro et al.

EGFRRandomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With Mutation (IMPACT)

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.